THE EFFECT OF COMBINATION THERAPY WITH GLICLAZIDE AND METFORMIN IN CONTROL OF BLOOD GLUCOSE OF TYPE 2 DIABETICS

Gliclazide is a second generation sulfonylurea which its efficacy and safety in the treatment of diabetes has been established. Diamicron MR (30 mg) is a new formulation of gliclazide with modified release which offer once daily dosage administration. This study was designed to assess the effect of combination therapy with diamicron and metformin in the treatment of type 2 diabetes. 16 patients with type 2 diabetes (2 males, 14 females) more than 35 years old who despite treatment with glibenclamide and metformin had poor diabetes control participated in this clinical trial.HbA1c, lipid profile, liver and renal function tests at the end of study were compared with before. No significant changes was found in FBS, BS2hpp, lipid profile and renal and liver function tests at the end of study. Patient's weight was stable during the study. Regardless of well efficacy of diamicron in the treatment of new diabetics cases, it is not recommended for patients with poor diabetes control despite of combination therapy with metformin and glibenclamide.